Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: oral antioxidant combination vs control Quality of life: Quality of Well Being score change from baseline · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant combination vs control Nutritional status: change from baseline in BMI · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant combination vs control Pulmonary exacerbations: mean time to next exacerbation · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant combination vs control Adverse events · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant mixed supplement vs control Lung function: FEV1 % predicted mean change from baseline · adults and children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant mixed supplement vs control Lung function: FEV1 % predicted mean change from baseline · adults and children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant mixed supplement vs control Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant mixed supplement vs control Nutritional status: change from baseline in BMI · adults and children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled antioxidants vs placebo Nutritional status: change from baseline in BMI · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled antioxidants vs placebo Pulmonary exacerbations: mean time to next exacerbation · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidants (NAC/GSH) vs placebo Pulmonary exacerbations: mean time to next exacerbation · adults and children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral vitamin E supplementation vs placebo or no treatment Lung function: FEV1 % predicted mean change from baseline · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral vitamin E supplementation vs placebo or no treatment Lung function: FEV1 % predicted mean change from baseline · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral vitamin E supplementation vs placebo or no treatment Quality of life · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ ivacaftor vs placebo QoL Total score · adults and children with cystic fibrosis and with at least one R117H CFTR mutation Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ ivacaftor vs placebo QoL Total score · adults and children with cystic fibrosis and with the F508del CFTR mutation Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ ivacaftor vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis and with the F508del CFTR mutation Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ ivacaftor vs placebo QoL Total score · adults and children with cystic fibrosis and with at least one G551D CFTR mutation Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of transfusion · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious adverse events · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Haeatological indices · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Duration of hospital stay · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum ferritin · participants with β‐thalassaemia Splenectomy for people with thalassaemia major or intermedia (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral magnesium pidolate vs placebo/no intervention Length of hospital stay · people with sickle cell disease Magnesium for treating sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral magnesium pidolate vs placebo/no intervention Change in dense red cells in sickle cell disease · people with sickle cell disease Magnesium for treating sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral magnesium pidolate vs placebo/no intervention Quality of life · people with sickle cell disease Magnesium for treating sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: cycled vs culture‐based antibiotic therapy Quality of life · children (aged 1 to 12 years) with CF and a newly isolated PA infection Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: cycled vs culture‐based antibiotic therapy Time to chronic PA · children (aged 1 to 12 years) with CF and a newly isolated PA infection Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Pharmacological intervention (pregabalin) vs placebo PGIC · adults and children with sickle cell disease experiencing neuropathic pain Interventions for treating neuropathic pain in people with sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Pharmacological intervention (pregabalin) vs placebo Time to improvement of symptoms · adults and children with sickle cell disease experiencing neuropathic pain Interventions for treating neuropathic pain in people with sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Pharmacological intervention (pregabalin) vs placebo Changes in sleep quality as measured by sleep questionnaires · adults and children with sickle cell disease experiencing neuropathic pain Interventions for treating neuropathic pain in people with sickle cell disease (2019) · Cochrane | no estimate extracted | NR | No studies |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · Immediate (<24 h) and delayed (24 h to 10 days) Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane | This outcome was not reported in either of the trials. | 0 studies | No studies |
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo (placebo solution/mouthwash) Number of thromboembolic complications · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and… Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral… (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo (placebo solution/mouthwash) Bleeding duration (minutes, all types of bleeding, minor and major) · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and… Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral… (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo (placebo solution/mouthwash) Change in haemoglobin level from baseline · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and… Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral… (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
Antifibrinolytic agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) vs Placebo, no intervention, or usual care Outcome NR · People on continuous direct oral anticoagulant (DOAC) treatment undergoing oral or dental procedures Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral… (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
Intervention NR Vitamin A deficiency disorders · children and adults with CF Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality · children and adults with CF Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes1 · 117 children with homozygous sickle cell (SS) disease Folate supplementation in people with sickle cell disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo (placebo solution/mouthwash) Amount of postoperative blood loss (mL) · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and… Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral… (2018) · Cochrane | no estimate extracted | 0 studies | No studies |
Intervention NR Abnormally large livers reduced to within normal limits, as measured by ultrasound · adults and children with cystic fibrosis‐related liver disease Ursodeoxycholic acid for cystic fibrosis‐related liver disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox vs deferiprone Satisfaction · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine LIC · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine Satisfaction with treatment · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine AE: serum creatinine increased · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferiprone vs deferiprone and deferoxamine Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferiprone vs deferiprone and deferoxamine Satisfaction · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox vs placebo Responder analysis · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |